- Home
- INFY vs REGN Comparison
INFY vs REGN Comparison
Compare INFY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INFY
- REGN
- Stock Information
- Founded
- INFY 1981
- REGN 1988
- Country
- INFY India
- REGN United States
- Employees
- INFY N/A
- REGN N/A
- Industry
- INFY EDP Services
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- INFY Technology
- REGN Health Care
- Exchange
- INFY Nasdaq
- REGN Nasdaq
- Market Cap
- INFY 77.7B
- REGN 63.4B
- IPO Year
- INFY 1999
- REGN 1991
- Fundamental
- Price
- INFY $18.72
- REGN $537.15
- Analyst Decision
- INFY Hold
- REGN Buy
- Analyst Count
- INFY 7
- REGN 22
- Target Price
- INFY $17.33
- REGN $839.91
- AVG Volume (30 Days)
- INFY 11.9M
- REGN 1.3M
- Earning Date
- INFY 07-17-2025
- REGN 08-01-2025
- Dividend Yield
- INFY 2.28%
- REGN 0.66%
- EPS Growth
- INFY N/A
- REGN 16.49
- EPS
- INFY 0.76
- REGN 39.43
- Revenue
- INFY $19,277,000,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- INFY $5.06
- REGN N/A
- Revenue Next Year
- INFY $7.39
- REGN $6.78
- P/E Ratio
- INFY $24.63
- REGN $13.56
- Revenue Growth
- INFY 3.85
- REGN 7.52
- 52 Week Low
- INFY $15.82
- REGN $476.49
- 52 Week High
- INFY $23.63
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- INFY 56.48
- REGN 46.90
- Support Level
- INFY $18.41
- REGN $514.79
- Resistance Level
- INFY $18.67
- REGN $531.21
- Average True Range (ATR)
- INFY 0.23
- REGN 11.96
- MACD
- INFY 0.01
- REGN 3.85
- Stochastic Oscillator
- INFY 78.00
- REGN 58.98
About INFY Infosys Limited
Infosys is a leading global IT services provider, with over 320,000 employees. Based in Bengaluru, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).